Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in June 2021 for pwCF ≥6 yrs of age. In this single...

Descripción completa

Detalles Bibliográficos
Autores principales: Schütz, Katharina, Pallenberg, Sophia Theres, Kontsendorn, Julia, DeLuca, David, Sukdolak, Cinja, Minso, Rebecca, Büttner, Tina, Wetzke, Martin, Dopfer, Christian, Sauer-Heilborn, Annette, Ringshausen, Felix C., Junge, Sibylle, Tümmler, Burkhard, Hansen, Gesine, Dittrich, Anna-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352657/
https://www.ncbi.nlm.nih.gov/pubmed/37469865
http://dx.doi.org/10.3389/fphar.2023.1171544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352657/
https://www.ncbi.nlm.nih.gov/pubmed/37469865
http://dx.doi.org/10.3389/fphar.2023.1171544

Ejemplares similares